SPY
736.53
+0.17%
QQQ
657.50
+0.21%
BTC/USD
75,772.45
+0.03%
DIA
512.52
+0.06%
GLD
373.37
+0.23%
TLT
81.85
−0.09%
Try
Free
US
Sign in
Register
My Account
Benzinga
Premium Services
Services
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
Pfizer Inc
PFE
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$29.39
-0.49
-1.64%
Last update: Nov 6, 7:58 PM
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Dividends
Compare
Options
Stock Report
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
Dividend:
The dividend Ex-Date was 2 days ago
Earnings:
Q3 2026 Earnings were released on Tue Nov 3rd, before the market open
Conference Call:
The most recent conference call started at 10:00 AM, 5 days ago
Click to view the webcast
Pfizer Financials
Pfizer (PFE) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Nasdaq Jumps Over 200 Points as Chip Stocks Gain: Fear & Greed Index Remains in ‘Extreme Fear’ Zone
Markets closed mixed as CNN Fear & Greed stayed at 19 (Extreme Fear); Nasdaq rose 0.83%, Dow fell, Apple dropped and Aehr surged 26%.
Avi Kapoor
Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings
U.S. stocks were mixed as Nasdaq gained 1%; Pfizer beat Q3 estimates and raised 2026 guidance, while oil, gold and European shares fell.
Avi Kapoor
Non-COVID Portfolio Steps Up: Pfizer Outpaces Consensus and Hikes Guidance
Pfizer beats Q3 revenue and profit forecasts on oncology and non-COVID drug growth, raising its full-year 2026 sales and EPS outlook.
Vandana Singh
PRO
Pfizer Q3 Prevnar Family Revenue Down 10% Operationally On Lower Vaccination Rates
Benzinga Newsdesk
PRO
Pfizer Q3 Eliquis Revenue Up 25% Operationally; Padcev Up 55%
Benzinga Newsdesk
PRO
Pfizer Q3 Paxlovid Revenue Down 63% Operationally; Comirnaty Down 29%
Benzinga Newsdesk
